RDHL

Redhill Biopharma
RDHL

1.24 USD
+0.04
3.33%
At close Updated Dec 1, 4:00 PM EST
Pre-market
After hours
1.22
-0.02
1.61%
1 day
3.33%
5 days
15.89%
1 month
-2.36%
3 months
-4.62%
6 months
-31.11%
Year to date
-80.63%
1 year
-84.86%
5 years
-99.99%
10 years
-99.99%
 

About: Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.

Employees: 35

Healthcare Drug Manufacturers - Specialty & Generic
0
Funds holding %
of 7,483 funds
Explore Fund Trends
–
Analysts bullish %
See Analyst Outlook
–
Positive news %
Check Journalist POV
Price charts implemented using Lightweight Charts™